---
title: "Cassava Sciences Publishes Phase 3 Simufilam Alzheimer’s Trial Results in JPAD"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/272415170.md"
description: "Cassava Sciences Inc. has published results from two Phase 3 trials of simufilam for Alzheimer’s disease in the Journal of Prevention of Alzheimer’s Disease. The trials did not meet their primary or secondary endpoints, but post-hoc analyses showed differences in specific patient subgroups. The drug demonstrated a favorable safety profile, but the company will not pursue further studies on simufilam for Alzheimer’s. The clinical data is now publicly accessible for further research."
datetime: "2026-01-13T13:01:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/272415170.md)
  - [en](https://longbridge.com/en/news/272415170.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/272415170.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/272415170.md) | [English](https://longbridge.com/en/news/272415170.md)


# Cassava Sciences Publishes Phase 3 Simufilam Alzheimer’s Trial Results in JPAD

Cassava Sciences Inc. has announced the publication of detailed results from two Phase 3 clinical trials, RETHINK-ALZ and REFOCUS-ALZ, evaluating simufilam in patients with mild-to-moderate Alzheimer’s disease. The results, now available in the Journal of Prevention of Alzheimer’s Disease, confirm that the studies did not meet their pre-specified co-primary, secondary, or exploratory biomarker endpoints. However, the publication includes exploratory post-hoc analyses that identified specific patient subgroups with observed differences between the higher dose of simufilam and placebo. The company reports that simufilam demonstrated a favorable safety profile in these trials. Cassava Sciences does not plan further studies of simufilam in Alzheimer’s disease, but has made the clinical data publicly accessible for ongoing research in the field. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cassava Sciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9624450) on January 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### 相關股票

- [Cassava Sciences (SAVA.US)](https://longbridge.com/zh-HK/quote/SAVA.US.md)
- [FILANA THERAPEUTICS INC (FLNA.US)](https://longbridge.com/zh-HK/quote/FLNA.US.md)

## 相關資訊與研究

- [Filana leaves Cassava roots behind amid branch into epilepsy](https://longbridge.com/zh-HK/news/278579055.md)
- [10:10 ETCaringKind Launches WeAreCaringKind.org & New Website, Expanding Access to Free Alzheimer's and Dementia Support](https://longbridge.com/zh-HK/news/278738105.md)
- [The quiet resurgence of plant-based illicit drugs](https://longbridge.com/zh-HK/news/278733066.md)
- [AstraZeneca and Daiichi secure US fast-track status for cancer drug](https://longbridge.com/zh-HK/news/278343765.md)
- [These 8 drugs could help fight dementia - and they're already on the market](https://longbridge.com/zh-HK/news/278280278.md)